THU0261 Outcomes in Systemic Lupus Erythematous (SLE) Patients with High Disease Activity Treated with Belimumab: Results from an Observational Study in the United States (U.S.)

Abstract

BackgroundPost hoc analyses of belimumab BLISS trials identified baseline factors generally associated with high disease activity as predictors of improved response to treatment, such as SELENA-SLEDAI (SS)> 10, low complement...